227 related articles for article (PubMed ID: 27267749)
1. Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies.
Vallat JM; Magy L; Ciron J; Corcia P; Le Masson G; Mathis S
Expert Rev Neurother; 2016 Sep; 16(9):1111-9. PubMed ID: 27267749
[TBL] [Abstract][Full Text] [Related]
2. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
3. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies.
Magy L; Kaboré R; Mathis S; Lebeau P; Ghorab K; Caudie C; Vallat JM
J Immunol Res; 2015; 2015():450391. PubMed ID: 26065001
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.
Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L
Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
7. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia.
Weiss MD; Dalakas MC; Lauter CJ; Willison HJ; Quarles RH
J Neuroimmunol; 1999 Mar; 95(1-2):174-84. PubMed ID: 10229128
[TBL] [Abstract][Full Text] [Related]
8. [Polyneuropathies and gammapathies: a form with antiglycoprotein MAG antibodies].
Steck AJ; Meier C; Vandevelde M; Regli F
Rev Neurol (Paris); 1984; 140(1):28-36. PubMed ID: 6198705
[TBL] [Abstract][Full Text] [Related]
9. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody.
Kawagashira Y; Koike H; Ohyama K; Hashimoto R; Iijima M; Adachi H; Katsuno M; Chapman M; Lunn M; Sobue G
J Neurol Sci; 2015 Jan; 348(1-2):67-73. PubMed ID: 25467141
[TBL] [Abstract][Full Text] [Related]
10. [Polyneuropathy involving cranial nerves associated with monoclonal IgM antibodies with anti-MAG/SGPG/SGPLG/sulfatides activity].
Drouet A; Caudie C; Vallat JM; Ruel JH; Felten D; Guilloton L; Giraud P
Rev Neurol (Paris); 2006 Jun; 162(6-7):760-6. PubMed ID: 16840988
[TBL] [Abstract][Full Text] [Related]
11. Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment.
Campagnolo M; Ferrari S; Dalla Torre C; Cabrini I; Cacciavillani M; Lucchetta M; Ruggero S; Toffanin E; Cavallaro T; Briani C
J Neuroimmunol; 2015 Apr; 281():1-4. PubMed ID: 25867460
[TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
Léger JM; Viala K; Nicolas G; Créange A; Vallat JM; Pouget J; Clavelou P; Vial C; Steck A; Musset L; Marin B;
Neurology; 2013 Jun; 80(24):2217-25. PubMed ID: 23667063
[TBL] [Abstract][Full Text] [Related]
13. Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy.
Baron M; Lozeron P; Harel S; Bengoufa D; Vignon M; Asli B; Malphettes M; Parquet N; Brignier A; Fermand JP; Kubis N; Arnulf B
J Neurol; 2017 Jun; 264(6):1132-1135. PubMed ID: 28484839
[TBL] [Abstract][Full Text] [Related]
14. [Dysimmune neuropathies: current diagnosis and therapy].
Léger JM; Larue S; Dashi F
Rev Prat; 2008 Nov; 58(17):1887-9, 1892-4. PubMed ID: 19157204
[TBL] [Abstract][Full Text] [Related]
15. Serum cytokine patterns in immunoglobulin m monoclonal gammopathy-associated polyneuropathy.
Stork ACJ; Rijkers GT; Vlam L; Cats EA; de Jong BAW; Fritsch-Stork RDE; Veldink JH; van den Berg LH; Notermans NC; van der Pol WL
Muscle Nerve; 2019 Jun; 59(6):694-698. PubMed ID: 30847948
[TBL] [Abstract][Full Text] [Related]
16. Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy.
Pascual-Goñi E; Martín-Aguilar L; Lleixà C; Martínez-Martínez L; Simón-Talero MJ; Díaz-Manera J; Cortés-Vicente E; Rojas-García R; Moga E; Juárez C; Illa I; Querol L
Sci Rep; 2019 Apr; 9(1):6155. PubMed ID: 30992531
[TBL] [Abstract][Full Text] [Related]
17. Delayed appearance of anti-myelin-associated glycoprotein antibodies in a patient with chronic demyelinating polyneuropathy.
Valldeoriola F; Graus F; Steck AJ; Muñoz E; de la Fuente M; Gallart T; Ribalta T; Bombí JA; Tolosa E
Ann Neurol; 1993 Sep; 34(3):394-6. PubMed ID: 7689821
[TBL] [Abstract][Full Text] [Related]
18. Anti-MAG IgM: differences in antibody tests and correlation with clinical findings.
Matà S; Ambrosini S; Saccomanno D; Biagioli T; Carpo M; Amantini A; Giannini F; Barilaro A; Toscani L; Del Mastio M; Comi GP; Sorbi S
Neurol Sci; 2020 Feb; 41(2):365-372. PubMed ID: 31654362
[TBL] [Abstract][Full Text] [Related]
19. Selective loss of myelin-associated glycoprotein from myelin correlates with anti-MAG antibody titre in demyelinating paraproteinaemic polyneuropathy.
Gabriel JM; Erne B; Miescher GC; Miller SL; Vital A; Vital C; Steck AJ
Brain; 1996 Jun; 119 ( Pt 3)():775-87. PubMed ID: 8673490
[TBL] [Abstract][Full Text] [Related]
20. Anti-myelin-associated glycoprotein neuropathy.
Steck AJ; Stalder AK; Renaud S
Curr Opin Neurol; 2006 Oct; 19(5):458-63. PubMed ID: 16969155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
